Evidence map›Paper›PMID 24464100›Full record

ArticleNature genetics2014

Identification of low-frequency and rare sequence variants associated with elevated or reduced risk of type 2 diabetes.

Valgerdur Steinthorsdottir, Gudmar Thorleifsson, Patrick Sulem, Hannes Helgason, Niels Grarup, Asgeir Sigurdsson, Hafdis T Helgadottir, Hrefna Johannsdottir, Olafur T Magnusson, Sigurjon A Gudjonsson and 24 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Nature genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 184 papers, 13 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
184citing papers in PubMed, 13 pooled it
44.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

184 citing papers in PubMed, 13 syntheses or guidelines pooled it, 329 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Association between SLC30A8 rs13266634 Polymorphism and Type 2 Diabetes Risk: A Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2015
    Pooled it
  13. Pooled it
  14. Trial
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

124 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors at 9 institutions in 3 countries.

Valgerdur SteinthorsdottirdeCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
Gudmar ThorleifssondeCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
Patrick SulemdeCODE Genetics/Amgen, Inc., Reykjavik, Iceland.ORCID 0000000171236123
Hannes Helgason1] deCODE Genetics/Amgen, Inc., Reykjavik, Iceland. [2] School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland.
Niels GrarupNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Asgeir SigurdssondeCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
Hafdis T HelgadottirdeCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
Hrefna JohannsdottirdeCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
Olafur T MagnussondeCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
Sigurjon A GudjonssondeCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
Johanne M JustesenNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Marie N HarderNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Marit E JørgensenSteno Diabetes Center, Gentofte, Denmark.
Cramer ChristensenDepartment of Internal Medicine and Endocrinology, Vejle Hospital, Vejle, Denmark.
Ivan Brandslund1] Department of Clinical Biochemistry, Vejle Hospital, Vejle, Denmark. [2] Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
Annelli SandbækDepartment of Public Health, Section of General Practice, University of Aarhus, Aarhus, Denmark.
Torsten LauritzenDepartment of Public Health, Section of General Practice, University of Aarhus, Aarhus, Denmark.
Henrik VestergaardNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Allan LinnebergResearch Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark.
Torben Jørgensen1] Research Centre for Prevention and Health, Glostrup University Hospital, Glostrup, Denmark. [2] Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. [3] Faculty of Medicine, University of Aalborg, Aalborg, Denmark.
Torben HansenNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Maryam S DaneshpourCellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohammad-Sadegh FallahCellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Astradur B HreidarssonDepartment of Endocrinology and Metabolism, Landspitali, National University Hospital of Iceland, Reykjavik, Iceland.
Gunnar SigurdssonDepartment of Endocrinology and Metabolism, Landspitali, National University Hospital of Iceland, Reykjavik, Iceland.
Fereidoun AziziEndocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Rafn BenediktssonDepartment of Endocrinology and Metabolism, Landspitali, National University Hospital of Iceland, Reykjavik, Iceland.
Gisli MassondeCODE Genetics/Amgen, Inc., Reykjavik, Iceland.
Agnar Helgason1] deCODE Genetics/Amgen, Inc., Reykjavik, Iceland. [2] Department of Anthropology, University of Iceland, Reykjavik, Iceland.
Augustine Kong1] deCODE Genetics/Amgen, Inc., Reykjavik, Iceland. [2] School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland.
Daniel F Gudbjartsson1] deCODE Genetics/Amgen, Inc., Reykjavik, Iceland. [2] School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland.
Oluf PedersenNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Unnur Thorsteinsdottir1] deCODE Genetics/Amgen, Inc., Reykjavik, Iceland. [2] Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
Kari Stefansson1] deCODE Genetics/Amgen, Inc., Reykjavik, Iceland. [2] Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
deCODE Genetics (Iceland) · ISUniversity of Copenhagen · DKNational University Hospital of Iceland · ISResearch Institute for Endocrine Sciences · IRAarhus University · DKGlostrup Hospital · DKSteno Diabetes Centers · DKUniversity of Southern Denmark · DKVejle Sygehus · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Through whole-genome sequencing of 2,630 Icelanders and imputation into 11,114 Icelandic cases and 267,140 controls followed by testing in Danish and Iranian samples, we discovered 4 previously unreported variants affecting risk of type 2 diabetes (T2D). A low-frequency (1.47%) variant in intron 1 of CCND2, rs76895963[G], reduces risk of T2D by half (odds ratio (OR) = 0.53, P = 5.0 × 10(-21)) and is correlated with increased CCND2 expression. Notably, this variant is also associated with both greater height and higher body mass index (1.17 cm per allele, P = 5.5 × 10(-12) and 0.56 kg/m(2) per allele, P = 6.5 × 10(-7), respectively). In addition, two missense variants in PAM, encoding p.Asp563Gly (frequency of 4.98%) and p.Ser539Trp (frequency of 0.65%), confer moderately higher risk of T2D (OR = 1.23, P = 3.9 × 10(-10) and OR = 1.47, P = 1.7 × 10(-5), respectively), and a rare (0.20%) frameshift variant in PDX1, encoding p.Gly218Alafs*12, associates with high risk of T2D (OR = 2.27, P = 7.3 × 10(-7)).

Indexed as

Genetic VariationAmidine-LyasesBody HeightBody WeightCase-Control StudiesCyclin D2DenmarkDiabetes Mellitus, Type 2FemaleGene FrequencyGenetic Predisposition to DiseaseGenome-Wide Association StudyHomeodomain ProteinsHumansIcelandIranAmidine-LyasesCCND2 protein, humanCyclin D2Homeodomain ProteinsMixed Function OxygenasesPAM protein, humanpancreatic and duodenal homeobox 1 proteinTrans-Activators

Identifiers

PMID24464100
OpenAlexW1972786933

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.